drugset / Trial / NCT02604914

A Sequential Two-Part, Open-Label Study in Healthy Male and Female Subjects

NCT02604914

Phase 1 Completed 36 enrolled NeuroDerm Ltd. Quotient Clinical · collab
RandomizedCrossoverOpen-labelTreatment

Summary

An Open-Label Study in Healthy Male and Female Subjects to Identify the Concentration that Provides Optimal Bioavailability of Levodopa Infused Subcutaneously via a Pump System; and to Compare the Bioavailability of Levodopa/Carbidopa Solution to that of Levodopa/Carbidopa Intestinal Gel (LCIG), Infused via a Naso-Jejunal Tube

Timeline

Start
2015-05-29
Primary completion
2016-06-30
Completion
2016-06-30

Drugs

EvaluationDrugModalityDoseRoute
Comparator LCIG Unknown Other
Subject ND0612 Unknown 0.24 ml Subcutaneous
Subject ND0612 Unknown 0.64 ml Subcutaneous

Indications